CORRECTION TO "USE OF ISOLATED HEPATOCYTE PREPARATIONS FOR CYTOCHROME P450 INHIBITION STUDIES: COMPARISON WITH MICROSOMES FOR K_1 DETERMINATION"

While processing the proof corrections for the article above [Brown HS, Chadwick A, and Houston JB (2007) Drug Metab Dispos 35:2119-2126], several superscript symbols used in the body of Tables 2 and 3, respectively, were not updated to reflect changes made to the table footnotes that define these symbols. The corrected tables appear below.

The online version of this article has been corrected in departure from the print version.

The printers regret this error and apologize for any confusion or inconvenience it may have caused.

Kinetic parameters for metabolism of dextromethorphan, midazolam, phenytoin, and tolbutamide in rat liver microsomes and freshly isolated hepatocytes Data are expressed as the mean of n = 3 (microsomes) and n = 4 (hepatocytes) \pm S.D.

Pathway	$V_{ m max}$	$K_{ m M}$	S ₅₀	Hill Coefficient	$K_{i,s}$	CL _{int}
	nmol/min	μM	μM	n	μM	μl/min
Dextrorphan	$0.53 \pm 0.04^{a,b} \\ 0.97 \pm 0.18^{a,c}$	0.42 ± 0.01^b 75 ± 12^c			448 ± 142	$1246 \pm 86^{a,b} 13.4 \pm 4.6^{a,c}$
3-Methoxymorphinan	1.30^{a}		65			$21.5 \pm 9.3^{a,d}$
1-Hydroxymidazolam	0.58 ± 0.07^{a}		11 ± 2	1.37 ± 0.17		$29 \pm 5^{a,d}$
4-Hydroxymidazolam	0.89 ± 0.17^a		9 ± 4	1.76 ± 0.17		$50 \pm 22^{a,d}$
5-(4-Hydroxyphenyl)-	0.027 ± 0.009^a	3.21 ± 0.56				$8.40 \pm 2.75^{a,b}$
5-Phenylhydantoin						$0.18 \pm 0.06^{a,c}$
4-Hydroxytolbutamide ^e	4.2^{a}	710				5.91^{a}
Dextrorphan	$0.08 \pm 0.02^{b,f}$	0.15 ± 0.03^{b}			645 ± 188	$545 \pm 50^{b,f}$
•	$0.48 \pm 0.11^{c,f}$	$10 \pm 3.6^{\circ}$				$49 \pm 9^{c,f}$
3-Methoxymorphinan	0.84^{f}		25			$31.3 \pm 6.1^{c,f}$
1-Hydroxymidazolam	0.28 ± 0.10^{f}	18 ± 6				16 ± 7^{f}
4-Hydroxymidazolam	0.17 ± 0.10^{f}	15 ± 7				12 ± 7^{f}
5-(4-Hydroxyphenyl)-	0.22 ± 0.05^f	5.23 ± 1.38				$43.3 \pm 7.4^{b.f}$
5-Phenylhydantoin						$0.39 \pm 0.27^{c,j}$
4-Hydroxytolbutamide ^e	0.74^{f}	650				1.14^{f}
	Dextrorphan 3-Methoxymorphinan 1-Hydroxymidazolam 4-Hydroxymidazolam 5-(4-Hydroxyphenyl)- 5-Phenylhydantoin 4-Hydroxytolbutamide ^e Dextrorphan 3-Methoxymorphinan 1-Hydroxymidazolam 4-Hydroxymidazolam 5-(4-Hydroxyphenyl)- 5-Phenylhydantoin	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Pathway V_{max} K_{M} S_{50} Coefficient nmol/min μM μM n Dextrorphan $0.53 \pm 0.04^{a,b}$ 0.42 ± 0.01^{b} $0.97 \pm 0.18^{a,c}$ 75 ± 12^{c} 3-Methoxymorphinan 1.30^{a} 65 11 ± 2 1.37 ± 0.17 4-Hydroxymidazolam 0.89 ± 0.17^{a} 9 ± 4 1.76 ± 0.17 5-(4-Hydroxyphenyl)- 0.027 ± 0.009^{a} 3.21 ± 0.56 5-Phenylhydantoin 4.2^{a} 710 Dextrorphan $0.08 \pm 0.02^{b/f}$ 0.15 ± 0.03^{b} 0.48 ± $0.11^{c/f}$ 10 ± 3.6^{c} 3-Methoxymorphinan 0.84^{f} 25 1-Hydroxymidazolam 0.28 ± 0.10^{f} 18 ± 6 4-Hydroxymidazolam 0.17 ± 0.10^{f} 15 ± 7 5-(4-Hydroxyphenyl)- 0.22 ± 0.05^{f} 5.23 ± 1.38 5-Phenylhydantoin	Pathway V_{max} K_{M} S_{50} Coefficient $K_{i,s}$ nmol/min μM μM n μM Dextrorphan $0.53 \pm 0.04^{a.b}$ 0.42 ± 0.01^b 448 ± 142 $0.97 \pm 0.18^{a.c}$ 75 ± 12^c 3-Methoxymorphinan 1.30^a 65 1-Hydroxymidazolam 0.58 ± 0.07^a 11 ± 2 1.37 ± 0.17 4-Hydroxyphenyllydarolam 5-(4-Hydroxyphenyllydantoin 0.027 ± 0.009^a 3.21 ± 0.56 3.21 ± 0.56 5-Phenylhydantoin 4.2^a 710 710 Dextrorphan 0.08 ± 0.02^{bf} 0.15 ± 0.03^b 645 ± 188 0.48 ± 0.11^{cf} 10 ± 3.6^c 25 3-Methoxymorphinan 0.84^f 25 1-Hydroxymidazolam 0.28 ± 0.10^f 18 ± 6 4-Hydroxymidazolam 0.17 ± 0.10^f 15 ± 7 5-(4-Hydroxyphenyllydantoin 0.22 ± 0.05^f 5.23 ± 1.38

^a Values expressed per milligram protein.

TABLE 3

Downloaded from dmd.aspetjournals.org at ASPET Journals on March 20, 2022

In vitro inhibition data in rat microsomes and hepatocytes obtained for substrates and inhibitors of CYP2C9, CYP2D6, and CYP3A4 In the present study microsomal values represent mean $(n = 3) \pm S.D.$ and hepatocyte values represent mean $(n = 4) \pm S.D.$

P450 Inhibitor	Pathway	Unbound K _i Values		Cell-to-Medium Ratio	Fraction Unbound in Incubation (fu _{inc})		K_i Ratio ^a
		Microsomes	Hepatocytes		Microsomes	Hepatocytes	
		μ.	М				
Miconazole	Hydroxy-tolbutamide	0.22 ± 0.06	0.22 ± 0.08	6000	0.06^{b}	0.06^{c}	1
Fluconazole	Hydroxy-tolbutamide	29 ± 0.4	16 ± 1.0	4.2	1^{b}	0.99^{c}	1.81
	1-Hydroxy midazolam	26	30				0.87
	4-Hydroxy midazolam	17.8	9				1.98
	Phenytoin	3.5	1.31				2.67
Ketoconazole	Hydroxy-tolbutamide	0.88 ± 0.30	0.44 ± 0.10	1200	0.23^{b}	0.26^{c}	2
	1-Hydroxy midazolam	0.08	1.19				0.07
	4-Hydroxy midazolam	0.05	0.04				1.25
	Phenytoin	0.19	0.28				0.68
Quinine	Dextrorphan	1.6 ± 0.65^d	1.4 ± 0.82^d	143^{e}	0.85^{f}	0.85^{g}	1.14
	Dextrorphan	3.0 ± 1.6^{h}	8.3 ± 1.32^{h}				0.36
	3-Methoxymorphinan	5.7 ± 2.6	6.2 ± 2.13				0.92
De	Dextrorphan	0.06 ± 0.03^d	0.15 ± 0.05^d	2010^{e}	0.51^{f}	0.28^{g}	0.4
	Dextrorphan	0.97 ± 0.47^{h}	0.58 ± 0.22^{h}				1.67
	3-Methoxymorphinan	1.5 ± 1.3	0.94 ± 0.22				1.60
Fluvoxamine	Dextrorphan	0.26 ± 0.02^d	0.44 ± 0.08^d	577 ^e	0.79^{f}	0.58^{g}	0.59
	Dextrorphan	1.4 ± 0.4^{h}	1.6 ± 0.21^{h}				0.88
	3-Methoxymorphinan	3.3 ± 1.38	0.99 ± 0.27				3.33

^a K_i ratio is represented as microsomal K_i/hepatocyte K_i.

^b Data for the high-affinity, low-capacity site.

^c Data for the low-affinity, high-capacity site.

^d CL_{max} (maximal clearance).

Tolbutamide data taken from Ashforth et al. (1995).

^f Values expressed per 10⁶ cells.

^b fu_{inc} determined at 0.5 mg/ml.

 $fu_{\rm inc}$ determined at 0.5×10^6 cells/ml.

^d Inhibition data for the high-affinity, low-capacity dextrorphan pathway.

Taken from Hallifax and Houston (2007).

f fuinc determined at 0.1 mg/ml.

 $f_{\rm u_{\rm inc}}$ determined at 0.25 \times 10⁶ cells/ml.

Inhibition data for the low-affinitiy, high-capacity dextrorphan pathway.